<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="314">
  <stage>Registered</stage>
  <submitdate>29/08/2005</submitdate>
  <approvaldate>5/09/2005</approvaldate>
  <actrnumber>ACTRN12605000298617</actrnumber>
  <trial_identification>
    <studytitle>Left ventricular diastolic function in lean and overweight subjects.</studytitle>
    <scientifictitle>Left ventricular diastolic function in lean and overweight subjects.</scientifictitle>
    <utrn />
    <trialacronym>LOVE</trialacronym>
    <secondaryid>Nil known</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Non-diabetic subjects with a spectrum of body mass ranging from lean (body mass index&lt;25kg/m2) to overweight (BMI 25kg/m2 or greater)</healthcondition>
    <conditioncode>
      <conditioncode1>Diet and nutrition</conditioncode1>
      <conditioncode2>Other diet and nutrition disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>A cross-sectional observational study of left ventricular diastolic function in non-diabetic subjects over a range of body mass.  No treatment intervention.</interventions>
    <comparator>Non-interventional/observational - cross-sectional comparisons across a range of body mass</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Early detection / Screening</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Diastolic function as assessed by transthoracic cardiac ultrasound, employing a variety of echo-Doppler techniques. Echocardiography done at 1 timepoint.</outcome>
      <timepoint>Cross-sectional</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Individual echo-Doppler parameters (including pulsed wave Doppler transmitral flow and tissue Doppler imaging).</outcome>
      <timepoint>Secondary outcomes measured only at one time point.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Non-invasive measures of arterial stiffness using pulse analysis techniques: central augmentation index and pulse wave velocity (Sphygmocor system, AtCor Medical); large (C1) and small (C2) artery compliance (PulseWave CR-2000 system, HDI).</outcome>
      <timepoint>Secondary outcomes measured only at one time point.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Subjects without diabetes (excluded by oral glucose tolerance test); lean subjects (BMI&lt;25kg/m2) with waist circumference &lt;94cm for men and &lt;88cm for women; overweight subjects (BMI 25kg/m2 or greater) with waist circumference 94cm or greater for men and 88cm or greater for women. </inclusivecriteria>
    <inclusiveminage>40</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>79</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Atrial fibrillation; abnormal thyroid function; history of cardiovascular disease (myocardial or cerebral ischaemia); other major systemic illness.  Lean subjects: impaired glucose tolerance, blood pressure&gt;140/80mmHg, fasting total cholesterol 6.0mmol/L or greater; fasting triglycerides 2.2mmol/L or greater; treatment for hypertension or dyslipidaemia.  Overweight subjects: blood pressure 150/90mmHg or greater; fasting total cholesterol&gt;7.0mmol/L; fasting triglycerides&gt;4.0mmol/L.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs>Screening</purposeobs>
    <duration>Cross-sectional</duration>
    <selection>Defined population</selection>
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>9/08/2005</anticipatedstartdate>
    <actualstartdate>21/10/2004</actualstartdate>
    <anticipatedenddate />
    <actualenddate>25/01/2006</actualenddate>
    <samplesize>100</samplesize>
    <actualsamplesize>76</actualsamplesize>
    <recruitmentstatus>Closed: follow-up complete</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Professor Gerald F Watts</primarysponsorname>
    <primarysponsoraddress>University of Western Australia School of Medicine and Pharmacology (Royal Perth Hospital Unit)
Level 4, Medical Research Foundation Building
Rear 50 Murray Street
PERTH, Western Australia, AUSTRALIA 6000</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>School of Medicine and Pharmacology, University of Western Australia (Royal Perth Hospital and Fremantle Hospital Units)</fundingname>
      <fundingaddress>Level 4, Medical Research Foundation Building
Rear 50 Murray Street
PERTH, Western Australia, AUSTRALIA 6000</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Other</fundingtype>
      <fundingname>Keogh Institute for Medical Research</fundingname>
      <fundingaddress>1st Floor, C Block
Sir Charles Gairdner Hospital
Hospital Avenue
NEDLANDS, Western Australia, AUSTRALIA 6009</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Echo Services</fundingname>
      <fundingaddress>Suite 13, Hollywood Specialist Centre
95 Monash Avenue
NEDLANDS, Western Australia, AUSTRALIA 6009</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Individual</sponsortype>
      <sponsorname>Professor Timothy ME Davis</sponsorname>
      <sponsoraddress>University of Western Australia School of Medicine and Pharmacology (Fremantle Hospital Unit)
7th Floor, T Block, Fremantle Hospital
Alma Street
FREMANTLE, Western Australia, AUSTRALIA 6160</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
    <secondarysponsor>
      <sponsortype>Individual</sponsortype>
      <sponsorname>Dr Philip J Currie</sponsorname>
      <sponsoraddress>Echo Services
Suite 13, Hollywood Specialist Centre
95 Monash Avenue
NEDLANDS, Western Australia, AUSTRALIA 6009</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
    <secondarysponsor>
      <sponsortype>Individual</sponsortype>
      <sponsorname>Dr Bronwyn GA Stuckey</sponsorname>
      <sponsoraddress>Keogh Institute for Medical Research
1st Floor, C Block
Sir Charles Gairdner Hospital
Hospital Avenue
NEDLANDS, Western Australia, AUSTRALIA 6009</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This cross-sectional (snapshot) study aims to measure the relaxation function of the heart (using ultrasound) in a group of people who do not have diabetes, who are of varying weight and body size (ranging from lean to overweight).</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Royal Perth Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate>26/08/2004</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Fremantle Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Keogh Institute for Medical Research</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Prof</title>
      <name>Gerald F Watts</name>
      <address>GPO Box X2213
Perth WA 6847</address>
      <phone>+61 8 92240248</phone>
      <fax>+61 8 92240246</fax>
      <email>Gerald.Watts@uwa.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Gerald F Watts</name>
      <address>GPO Box X2213
Perth WA 6847</address>
      <phone>+61892240248</phone>
      <fax>+61892240246</fax>
      <email>Gerald.Watts@uwa.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Gerald F Watts</name>
      <address>University of Western Australia School of Medicine and Pharmacology
Level 4, Medical Research Foundation Building
Rear 50 Murray Street
PERTH, Western Australia, AUSTRALIA 6000</address>
      <phone>+61892240248</phone>
      <fax />
      <email>Gerald.Watts@uwa.edu.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>